103 related articles for article (PubMed ID: 9215840)
1. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia.
Liberato NL; Quaglini S; Barosi G
J Clin Oncol; 1997 Jul; 15(7):2673-82. PubMed ID: 9215840
[TBL] [Abstract][Full Text] [Related]
2. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
Beck JR; Guilhot J; Giles FJ; Aoki N; Wirt DP; Guilhot F
Leuk Lymphoma; 2001 Mar; 41(1-2):117-24. PubMed ID: 11342363
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia.
Kattan MW; Inoue Y; Giles FJ; Talpaz M; Ozer H; Guilhot F; Zuffa E; Huber SL; Beck JR
Ann Intern Med; 1996 Oct; 125(7):541-8. PubMed ID: 8815752
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma.
Wirt DP; Giles FJ; Oken MM; Solal-Celigny P; Beck JR
Leuk Lymphoma; 2001 Feb; 40(5-6):565-79. PubMed ID: 11426529
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
Aggarwal R; Ghoshal UC; Naik SR
Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
Dalziel K; Round A; Garside R; Stein K
Pharmacoeconomics; 2005; 23(5):515-26. PubMed ID: 15896102
[TBL] [Abstract][Full Text] [Related]
8. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
[TBL] [Abstract][Full Text] [Related]
9. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.
Bennett WG; Inoue Y; Beck JR; Wong JB; Pauker SG; Davis GL
Ann Intern Med; 1997 Nov; 127(10):855-65. PubMed ID: 9382363
[TBL] [Abstract][Full Text] [Related]
10. [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ].
Groot MT; Ossenkoppele GJ; Kramer MH; van den Boom G; Huijgens PC; Uyl-de Groot CA
Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1460-5. PubMed ID: 12908349
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.
Hillner BE; Kirkwood JM; Atkins MB; Johnson ER; Smith TJ
J Clin Oncol; 1997 Jun; 15(6):2351-8. PubMed ID: 9196150
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C: an economic evaluation of extended treatment with interferon.
Shiell A; Brown S; Farrell GC
Med J Aust; 1999 Aug; 171(4):189-93. PubMed ID: 10494234
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.
Wong JB; Koff RS; Tinè F; Pauker SG
Ann Intern Med; 1995 May; 122(9):664-75. PubMed ID: 7702228
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of peginterferon alpha-2a and peginterferon alpha-2b combination regimens in genotype-1 naive patients with chronic hepatitis C.
Gheorghe L; Baculea S
Hepatogastroenterology; 2010; 57(101):939-44. PubMed ID: 21033255
[TBL] [Abstract][Full Text] [Related]
20. Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.
Sacchi S; Kantarjian HM; Smith TL; O'Brien S; Pierce S; Kornblau S; Beran M; Keating MJ; Talpaz M
J Clin Oncol; 1998 Mar; 16(3):882-9. PubMed ID: 9508169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
